9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USES THEREOF
Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.
1 - 10 . (canceled)
11 . A method of treating a human subject in need of treatment for a bacterial skin or skin structure infection, comprising orally administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days, wherein said bacterial skin or skin structure infection is known or suspected to be caused by Gram-positive pathogens.
12 - 16 . (canceled)
17 . A method of treating a human subject in need of treatment for a bacterial skin or skin structure infection, comprising orally administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days, wherein said bacterial skin or skin structure infection is a result of vascular insufficiency or edema.
18 . (canceled)
19 . A method of treating a human subject in need of treatment for a bacterial skin or skin structure infection, comprising orally administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days, wherein each oral dose of said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered about 24 hours apart.
20 - 21 . (canceled)
22 . A method of treating a human subject in need of treatment for a bacterial skin or skin structure infection, comprising orally administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days, wherein said subject is treated for 8 days.
23 - 25 . (canceled)
26 . The method of claim 11 , wherein said Gram-positive pathogens include Staphylococcus aureus that is methicillin-resistant Staphylococcus aureus (MRSA), or methicillin-susceptible Staphylococcus aureus (MSSA).
27 . The method of claim 11 , wherein said Gram-positive pathogens include Streptococcus species that include Streptococcus anginosus group.
28 . The method of claim 11 , wherein said Gram-positive pathogens include Streptococcus species that include beta-hemolytic Streptococci or S. anginosus.
29 . The method of claim 11 , wherein said Gram-positive pathogens include Streptococcus species that include non-hemolytic Streptococci or S. intermedius.
30 . The method of claim 11 , wherein said Gram-positive pathogens include Streptococcus species that include alpha-hemolytic Streptococci or S. constellatus.
31 . The method of claim 11 , wherein said Gram-positive pathogens include Enterococcus species that include Enterococcus faecalis (VSE).
32 . The method of claim 11 , wherein said Gram-positive pathogens include Streptococcus species that include Streptococcus pyogenes.
33 . A method of treating a human subject in need of treatment for a bacterial skin or skin structure infection, comprising orally administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days, wherein said bacterial skin or skin structure infection is known or suspected to be caused by Gram-negative pathogens.
34 . (canceled)
35 . A method of treating a human subject in need of treatment for a bacterial skin or skin structure infection, comprising orally administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days, wherein GI adverse events (AEs) associated with treatment are predominantly mild.
36 . A method of treating a human subject in need of treatment for a bacterial skin or skin structure infection, comprising orally administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days, wherein GI adverse events (AEs) associated with treatment do not result in discontinuation of therapy.
37 - 48 . (canceled)